{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T14:10:19Z","timestamp":1793110219745,"version":"4.5.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T00:00:00Z","timestamp":1772928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Mechanism Study on Multifunctional Nanodrug Carriers Targeting Interleukin for Precise Anticancer Treatment of Breast Cancer, Zhejiang Provincial Medical and Health Science and Technology Plan Project","award":["2023RC076"],"award-info":[{"award-number":["2023RC076"]}]},{"name":"Anhui Hongde Shan Yi Medical Development and Medical Assistance Foundation","award":["KYZX2024003"],"award-info":[{"award-number":["KYZX2024003"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nanobiotechnol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The immunosuppressive tumor microenvironment and immune evasion mechanisms inhibit the development of effective antitumor responses and enduring immune memory, thereby diminishing the efficacy of cancer immunotherapy. In situ vaccines (ISVs) have been developed to overcome these challenges by inducing localized immunogenic cell death (ICD) and activating systemic immunity via dendritic cells (DCs) and CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cells. In this study, we engineered ferrous sulfide\u2013bovine serum albumin\u2013cell membrane nanoclusters to trigger ferroptosis, which were co-encapsulated with the photothermal agent indocyanine green in a thermosensitive hydrogel. This platform enables near-infrared-responsive drug release and works with sorafenib to boost ferroptosis. Mechanistic studies revealed that this combined regimen markedly enhanced DC-mediated antigen presentation and CD8\n                    <jats:sup>+<\/jats:sup>\n                    T-cell infiltration, leading to substantial antitumor efficacy and complete eradication of distant liver metastases. Ultimately, the indocyanine green\u2013ferrous sulfide\u2013bovine serum albumin\u2013cell membrane hydrogel\u2013sorafenib system induces ferroptosis-driven ICD, promoting an ISV-like effect that activates systemic antitumor immunity and demonstrates strong therapeutic efficacy, suggesting its potential as a novel cancer treatment strategy.\n                  <\/jats:p>","DOI":"10.1186\/s12951-026-04262-z","type":"journal-article","created":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T03:15:56Z","timestamp":1772939756000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Ferroptosis-driven in situ vaccine-like antitumor effects: NIR-triggered IFBM hydrogel synergizes with sorafenib to unleash systemic antitumor immunity"],"prefix":"10.1186","volume":"24","author":[{"given":"Zilong","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixian","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaqi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihua","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guodong","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,8]]},"reference":[{"issue":"12","key":"4262_CR1","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1038\/s41423-024-01226-x","volume":"21","author":"Y Liu","year":"2024","unstructured":"Liu Y, et al. Immunotherapy for glioblastoma: current state, challenges, and future perspectives. Cell Mol Immunol. 2024;21(12):1354\u201375. https:\/\/doi.org\/10.1038\/s41423-024-01226-x.","journal-title":"Cell Mol Immunol"},{"issue":"1","key":"4262_CR2","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41392-024-02108-4","volume":"10","author":"X Xiong","year":"2025","unstructured":"Xiong X, et al. Breast cancer: pathogenesis and treatments. Signal Transduct Target Ther. 2025;10(1):49. https:\/\/doi.org\/10.1038\/s41392-024-02108-4.","journal-title":"Signal Transduct Target Ther"},{"key":"4262_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2020.120224","author":"KY Wang","year":"2020","unstructured":"Wang KY, et al. An exosome-like programmable-bioactivating paclitaxel prodrug nanoplatform for enhanced breast cancer metastasis inhibition. Biomaterials. 2020. https:\/\/doi.org\/10.1016\/j.biomaterials.2020.120224.","journal-title":"Biomaterials"},{"issue":"10","key":"4262_CR4","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1038\/ni.2406","volume":"13","author":"J Banchereau","year":"2012","unstructured":"Banchereau J, Pascual V, O\u2019Garra A. From IL-2 to IL-37: the expanding spectrum of anti-inflammatory cytokines. Nat Immunol. 2012;13(10):925\u201331. https:\/\/doi.org\/10.1038\/ni.2406.","journal-title":"Nat Immunol"},{"issue":"12","key":"4262_CR5","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/nrc3380","volume":"12","author":"DV Krysko","year":"2012","unstructured":"Krysko DV, et al. Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer. 2012;12(12):860\u201375. https:\/\/doi.org\/10.1038\/nrc3380.","journal-title":"Nat Rev Cancer"},{"issue":"11","key":"4262_CR6","doi-asserted-by":"publisher","first-page":"10637","DOI":"10.1021\/acsnano.3c01733","volume":"17","author":"H Ye","year":"2023","unstructured":"Ye H, et al. Situ Sprayed Nanovaccine Suppressing Exosomal PD-L1 by Golgi Apparatus Disorganization for Postsurgical Melanoma Immunotherapy. ACS Nano. 2023;17(11):10637\u201350. https:\/\/doi.org\/10.1021\/acsnano.3c01733.","journal-title":"ACS Nano"},{"issue":"8","key":"4262_CR7","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1038\/s41423-025-01316-4","volume":"22","author":"K Peng","year":"2025","unstructured":"Peng K, et al. Eliciting antitumor immunity via therapeutic cancer vaccines. Cell Mol Immunol. 2025;22(8):840\u201368. https:\/\/doi.org\/10.1038\/s41423-025-01316-4.","journal-title":"Cell Mol Immunol"},{"key":"4262_CR8","doi-asserted-by":"publisher","unstructured":"Zhou Q, et al. Ferroptosis in cancer: From molecular mechanisms to therapeutic strategies. Signal Transduct Target Therapy. 2024;9(1). https:\/\/doi.org\/10.1038\/s41392-024-01769-5.","DOI":"10.1038\/s41392-024-01769-5"},{"key":"4262_CR9","doi-asserted-by":"publisher","unstructured":"Ye H, et al. Insights into the Biological Activity and Bio-Interaction Properties of Nanoscale Imine-Based 2D and 3D Covalent Organic Frameworks. Adv Sci. 2024;11(44). https:\/\/doi.org\/10.1002\/advs.202407391.","DOI":"10.1002\/advs.202407391"},{"issue":"4","key":"4262_CR10","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.ccell.2024.03.011","volume":"42","author":"G Lei","year":"2024","unstructured":"Lei G, Zhuang L, Gan B. The roles of ferroptosis in cancer: Tumor suppression, tumor microenvironment, and therapeutic interventions. Cancer Cell. 2024;42(4):513\u201334. https:\/\/doi.org\/10.1016\/j.ccell.2024.03.011.","journal-title":"Cancer Cell"},{"issue":"5","key":"4262_CR11","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.immuni.2024.03.019","volume":"57","author":"HN Bell","year":"2024","unstructured":"Bell HN, Stockwell BR, Zou W. Ironing out the role of ferroptosis in immunity. Immunity. 2024;57(5):941\u201356. https:\/\/doi.org\/10.1016\/j.immuni.2024.03.019.","journal-title":"Immunity"},{"key":"4262_CR12","doi-asserted-by":"publisher","unstructured":"Deng W, et al. The application of nanoparticles-based ferroptosis, pyroptosis and autophagy in cancer immunotherapy. J Nanobiotechnol. 2024;22(1). https:\/\/doi.org\/10.1186\/s12951-024-02297-8.","DOI":"10.1186\/s12951-024-02297-8"},{"issue":"43","key":"4262_CR13","doi-asserted-by":"publisher","first-page":"29804","DOI":"10.1021\/acsnano.4c09500","volume":"18","author":"Q Tang","year":"2024","unstructured":"Tang Q, et al. Intracellular Magnetic Hyperthermia Sensitizes Sorafenib to Orthotopic Hepatocellular Carcinoma Via Amplified Ferroptosis. ACS Nano. 2024;18(43):29804\u201319. https:\/\/doi.org\/10.1021\/acsnano.4c09500.","journal-title":"ACS Nano"},{"key":"4262_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1207496","author":"L Guo","year":"2023","unstructured":"Guo L, et al. Mechanism of sorafenib resistance associated with ferroptosis in HCC. Front Pharmacol. 2023. https:\/\/doi.org\/10.3389\/fphar.2023.1207496.","journal-title":"Front Pharmacol"},{"issue":"22","key":"4262_CR15","doi-asserted-by":"publisher","first-page":"6272","DOI":"10.1039\/d0bm01168a","volume":"8","author":"Z Li","year":"2020","unstructured":"Li Z, Rong L. Cascade reaction-mediated efficient ferroptosis synergizes with immunomodulation for high-performance cancer therapy. Biomaterials Sci. 2020;8(22):6272\u201385. https:\/\/doi.org\/10.1039\/d0bm01168a.","journal-title":"Biomaterials Sci"},{"key":"4262_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.carbpol.2025.124098","author":"Z Xu","year":"2025","unstructured":"Xu Z, et al. A host\/guest assembled hyaluronic acid-based supramolecular hydrogel with NIR-steered degradation capacity for enhanced tumor therapy through programmable drug release. Carbohydr Polym. 2025. https:\/\/doi.org\/10.1016\/j.carbpol.2025.124098.","journal-title":"Carbohydr Polym"},{"key":"4262_CR17","doi-asserted-by":"publisher","unstructured":"Mohammadzadeh V, et al. Hydrogels as advanced drug delivery platforms for cancer immunotherapy: promising innovations and future outlook. J Nanobiotechnol. 2025;23(1). https:\/\/doi.org\/10.1186\/s12951-025-03613-6.","DOI":"10.1186\/s12951-025-03613-6"},{"issue":"7","key":"4262_CR18","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1039\/c8cs00618k","volume":"48","author":"Y Liu","year":"2019","unstructured":"Liu Y, et al. Photothermal therapy and photoacoustic imaging\u2009<\u2009i>via nanotheranostics in fighting cancer. Chem Soc Rev. 2019;48(7):2053\u2013108. https:\/\/doi.org\/10.1039\/c8cs00618k.","journal-title":"Chem Soc Rev"},{"issue":"2","key":"4262_CR19","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1002\/cac2.12250","volume":"42","author":"L Zhao","year":"2022","unstructured":"Zhao L, et al. Ferroptosis in cancer and cancer immunotherapy. Cancer Commun. 2022;42(2):88\u2013116. https:\/\/doi.org\/10.1002\/cac2.12250.","journal-title":"Cancer Commun"},{"issue":"4","key":"4262_CR20","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/s41580-020-00324-8","volume":"22","author":"XJ Jiang","year":"2021","unstructured":"Jiang XJ, Stockwell BR, Conrad M. Ferroptosis: mechanisms, biology and role in disease. Nat Rev Mol Cell Biol. 2021;22(4):266\u201382. https:\/\/doi.org\/10.1038\/s41580-020-00324-8.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"4262_CR21","doi-asserted-by":"publisher","unstructured":"Efimova I, et al. Vaccination with early ferroptotic cancer cells induces efficient antitumor immunity. J Immunother Cancer. 2020;8(2). https:\/\/doi.org\/10.1136\/jitc-2020-001369.","DOI":"10.1136\/jitc-2020-001369"},{"issue":"4","key":"4262_CR22","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.chembiol.2020.02.005","volume":"27","author":"J Liu","year":"2020","unstructured":"Liu J, et al. Autophagy-Dependent Ferroptosis: Machinery and Regulation. Cell Chem Biology. 2020;27(4):420\u201335. https:\/\/doi.org\/10.1016\/j.chembiol.2020.02.005.","journal-title":"Cell Chem Biology"},{"key":"4262_CR23","doi-asserted-by":"publisher","unstructured":"Tang R, et al. Ferroptosis, necroptosis, and pyroptosis in anticancer immunity. J Hematol Oncol. 2020;13(1). https:\/\/doi.org\/10.1186\/s13045-020-00946-7.","DOI":"10.1186\/s13045-020-00946-7"},{"key":"4262_CR24","doi-asserted-by":"publisher","unstructured":"Yu B, et al. Magnetic field boosted ferroptosis-like cell death and responsive MRI using hybrid vesicles for cancer immunotherapy. Nat Commun. 2020;11(1). https:\/\/doi.org\/10.1038\/s41467-020-17380-5.","DOI":"10.1038\/s41467-020-17380-5"},{"key":"4262_CR25","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.semcancer.2019.03.002","volume":"66","author":"BR Zhou","year":"2020","unstructured":"Zhou BR, et al. Ferroptosis is a type of autophagy-dependent cell death. Sem Cancer Biol. 2020;66:89\u2013100. https:\/\/doi.org\/10.1016\/j.semcancer.2019.03.002.","journal-title":"Sem Cancer Biol"},{"issue":"6","key":"4262_CR26","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1038\/s41418-020-00719-2","volume":"28","author":"X Luo","year":"2021","unstructured":"Luo X, et al. Oxygenated phosphatidylethanolamine navigates phagocytosis of ferroptotic cells by interacting with TLR2. Cell Death Differ. 2021;28(6):1971\u201389. https:\/\/doi.org\/10.1038\/s41418-020-00719-2.","journal-title":"Cell Death Differ"},{"issue":"5","key":"4262_CR27","doi-asserted-by":"publisher","first-page":"5662","DOI":"10.1021\/acsnano.9b00892","volume":"13","author":"F Zhang","year":"2019","unstructured":"Zhang F, et al. Engineering Magnetosomes for Ferroptosis\/Immunomodulation Synergism in Cancer. ACS Nano. 2019;13(5):5662\u201373. https:\/\/doi.org\/10.1021\/acsnano.9b00892.","journal-title":"ACS Nano"},{"issue":"22","key":"4262_CR28","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1016\/j.scib.2021.02.026","volume":"66","author":"S Xu","year":"2021","unstructured":"Xu S, Min JX, Wang FD. Ferroptosis: an emerging player in immune cells. Sci Bull. 2021;66(22):2257\u201360. https:\/\/doi.org\/10.1016\/j.scib.2021.02.026.","journal-title":"Sci Bull"},{"key":"4262_CR29","doi-asserted-by":"publisher","unstructured":"Xiao Y, Yu DH. Tumor microenvironment as a therapeutic target in cancer. Pharmacol Ther. 2021;221. https:\/\/doi.org\/10.1016\/j.pharmthera.2020.107753. .","DOI":"10.1016\/j.pharmthera.2020.107753"},{"key":"4262_CR30","doi-asserted-by":"publisher","unstructured":"Yi M, et al. Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions. Mol Cancer. 2022;21(1). https:\/\/doi.org\/10.1186\/s12943-021-01489-2.","DOI":"10.1186\/s12943-021-01489-2"},{"key":"4262_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2022.102312","author":"ZH Lin","year":"2022","unstructured":"Lin ZH, et al. Hypoxia-induced HIF-1\u03b1\/lncRNA-PMAN inhibits ferroptosis by promoting the cytoplasmic translocation of ELAVL1 in peritoneal dissemination from gastric cancer. Redox Biol. 2022. https:\/\/doi.org\/10.1016\/j.redox.2022.102312.","journal-title":"Redox Biol"},{"key":"4262_CR32","doi-asserted-by":"publisher","unstructured":"Hao XP, et al. Inhibition of APOC1 promotes the transformation of M2 into M1 macrophages via the ferroptosis pathway and enhances anti-PD1 immunotherapy in hepatocellular carcinoma based on single-cell RNA sequencing. Redox Biol. 2022;56. https:\/\/doi.org\/10.1016\/j.redox.2022.102463.","DOI":"10.1016\/j.redox.2022.102463"},{"key":"4262_CR33","doi-asserted-by":"publisher","unstructured":"Zhang C, et al. Ferroptosis in cancer therapy: a novel approach to reversing drug resistance. Mol Cancer. 2022;21(1). https:\/\/doi.org\/10.1186\/s12943-022-01530-y.","DOI":"10.1186\/s12943-022-01530-y"},{"issue":"2","key":"4262_CR34","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.drudis.2021.10.011","volume":"27","author":"W Liu","year":"2022","unstructured":"Liu W, et al. Targeting regulated cell death (RCD) with small-molecule compounds in cancer therapy: A revisited review of apoptosis, autophagy-dependent cell death and necroptosis. Drug Discovery Today. 2022;27(2):612\u201325. https:\/\/doi.org\/10.1016\/j.drudis.2021.10.011.","journal-title":"Drug Discovery Today"},{"key":"4262_CR35","doi-asserted-by":"publisher","first-page":"5429","DOI":"10.2147\/ott.S254995","volume":"13","author":"YC Zhao","year":"2020","unstructured":"Zhao YC, et al. The Role of Erastin in Ferroptosis and Its Prospects in Cancer Therapy. Oncotargets Therapy. 2020;13:5429\u201341. https:\/\/doi.org\/10.2147\/ott.S254995.","journal-title":"Oncotargets Therapy"},{"key":"4262_CR36","doi-asserted-by":"publisher","unstructured":"Fucikova J, et al. Detection of immunogenic cell death and its relevance for cancer therapy. Cell Death Dis. 2020;11(11). https:\/\/doi.org\/10.1038\/s41419-020-03221-2.","DOI":"10.1038\/s41419-020-03221-2"},{"issue":"22","key":"4262_CR37","doi-asserted-by":"publisher","first-page":"7038","DOI":"10.1111\/febs.16059","volume":"289","author":"J Liu","year":"2022","unstructured":"Liu J, Kang R, Tang DL. Signaling pathways and defense mechanisms of ferroptosis. FEBS J. 2022;289(22):7038\u201350. https:\/\/doi.org\/10.1111\/febs.16059.","journal-title":"FEBS J"},{"key":"4262_CR38","doi-asserted-by":"publisher","unstructured":"Yao FP, et al. Iron regulatory protein 1 promotes ferroptosis by sustaining cellular iron homeostasis in melanoma. Oncol Lett. 2021;22(3). https:\/\/doi.org\/10.3892\/ol.2021.12918.","DOI":"10.3892\/ol.2021.12918"},{"key":"4262_CR39","doi-asserted-by":"publisher","unstructured":"Rafiq Z, et al. Enhancing immunotherapy efficacy with synergistic low-dose radiation in metastatic melanoma: current insights and prospects. J Experimental Clin Cancer Res. 2025;44(1). https:\/\/doi.org\/10.1186\/s13046-025-03281-2.","DOI":"10.1186\/s13046-025-03281-2"},{"key":"4262_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2023.1296935","author":"YL Liu","year":"2023","unstructured":"Liu YL, et al. Crosstalk between lipid metabolism and ferroptosis in cardiovascular diseases. Front Cardiovasc Med. 2023. https:\/\/doi.org\/10.3389\/fcvm.2023.1296935.","journal-title":"Front Cardiovasc Med"},{"issue":"5","key":"4262_CR41","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1038\/s41571-020-00462-0","volume":"18","author":"X Chen","year":"2021","unstructured":"Chen X, et al. Broadening horizons: the role of ferroptosis in cancer. Nat Reviews Clin Oncol. 2021;18(5):280\u201396. https:\/\/doi.org\/10.1038\/s41571-020-00462-0.","journal-title":"Nat Reviews Clin Oncol"},{"issue":"7860","key":"4262_CR42","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/s41586-021-03539-7","volume":"593","author":"C Mao","year":"2021","unstructured":"Mao C, et al. DHODH-mediated ferroptosis defence is a targetable vulnerability in cancer. Nature. 2021;593(7860):586\u2013. https:\/\/doi.org\/10.1038\/s41586-021-03539-7.","journal-title":"Nature"},{"key":"4262_CR43","doi-asserted-by":"publisher","unstructured":"Shen ZY, et al. Emerging Strategies of Cancer Therapy Based on Ferroptosis. Adv Mater. 2018;30(12). https:\/\/doi.org\/10.1002\/adma.201704007.","DOI":"10.1002\/adma.201704007"},{"key":"4262_CR44","doi-asserted-by":"publisher","unstructured":"Mikhail AS, et al. Hydrogel drug delivery systems for minimally invasive local immunotherapy of cancer. Adv Drug Deliv Rev. 2023;202. https:\/\/doi.org\/10.1016\/j.addr.2023.115083.","DOI":"10.1016\/j.addr.2023.115083"},{"issue":"4","key":"4262_CR45","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/nrclinonc.2016.168","volume":"14","author":"A Goodman","year":"2017","unstructured":"Goodman A, Patel SP, Kurzrock R. PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas. Nat Reviews Clin Oncol. 2017;14(4):203\u201320. https:\/\/doi.org\/10.1038\/nrclinonc.2016.168.","journal-title":"Nat Reviews Clin Oncol"},{"issue":"7755","key":"4262_CR46","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-019-1170-y","volume":"569","author":"WM Wang","year":"2019","unstructured":"Wang WM, et al. CD8\u2009+\u2009T cells regulate tumour ferroptosis during cancer immunotherapy. Nature. 2019;569(7755):270\u2013. https:\/\/doi.org\/10.1038\/s41586-019-1170-y.","journal-title":"Nature"},{"issue":"8","key":"4262_CR47","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1016\/j.ccell.2024.07.002","volume":"42","author":"U Uslu","year":"2024","unstructured":"Uslu U, Castelli S, June CH. CAR T cell combination therapies to treat cancer. Cancer Cell. 2024;42(8):1319\u201325. https:\/\/doi.org\/10.1016\/j.ccell.2024.07.002.","journal-title":"Cancer Cell"}],"container-title":["Journal of Nanobiotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12951-026-04262-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-026-04262-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-026-04262-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T10:27:35Z","timestamp":1776248855000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12951-026-04262-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,8]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4262"],"URL":"https:\/\/doi.org\/10.1186\/s12951-026-04262-z","relation":{},"ISSN":["1477-3155"],"issn-type":[{"value":"1477-3155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,8]]},"assertion":[{"value":"23 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"362"}}